Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy, in patients with rheumatoid arthritis

被引：0
|
作者：
Nishimoto, N. [1 ]
Miyasaka, N. [2 ]
Yamamoto, K. [3 ]
Kawai, S. [4 ]
Takeuchi, T. [5 ]
Azuma, J. [6 ]
Kishimoto, T. [7 ]
机构：
[1] Osaka Univ, Grad Sch Frontier Biosci, Immune Lab Regulat, Suita, Osaka, Japan
[2] Tokyo Med & Dent Univ, Dept Med Rheumatol, Tokyo, Japan
[3] Univ Tokyo, Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan
[4] Toho Univ, Omori Med Ctr, Div Rheumatol, Tokyo, Japan
[5] Saitama Med Ctr, Saitama Med Sch, Dept Rheumatol & Clin Immunol, Kawagoe, Saitama, Japan
[6] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Clin Evaluat Med & Therapeut, Suita, Osaka 565, Japan
[7] Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Osaka, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [31] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [32] Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis
    Ahmed A. El-Zayadi
    Sara A. Mohamed
    Mohammad Arafa
    Shereen M. Mohammed
    Abdelhady Zayed
    Mohamed S. Abdelhafez
    Ahmed M. Badawy
    Immunologic Research, 2020, 68 : 389 - 397
  • [33] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Yoshizaki, K
    Nishimoto, N
    Mihara, M
    Kishimoto, T
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2): : 247 - 259
  • [34] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [35] Targeting the IL-6 receptor with the monoclonal antibody tocilizumab significantly improves quality of life in patients with rheumatoid arthritis
    Smolen, J.
    Atkins, C.
    Rovensky, J.
    Ramos-Remus, C.
    Lucero, M.
    Woodworth, T.
    Alten, R.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1181 - 1182
  • [36] Cytomegalovirus Reactivation Induced Acute Hepatitis and Gastric Erosions in a Patient with Rheumatoid Arthritis under Treatment with an Anti-IL-6 Receptor Antibody, Tocilizumab
    Komura, Takuya
    Ohta, Hajime
    Nakai, Ryotaro
    Seishima, Jun
    Yamato, Masatoshi
    Miyazawa, Masaki
    Kaji, Kiichiro
    Marukawa, Yohei
    Kagaya, Takashi
    Kitagawa, Kiyoki
    Kawashima, Atsuhiro
    Kaneko, Shuichi
    Unoura, Masashi
    INTERNAL MEDICINE, 2016, 55 (14) : 1923 - 1927
  • [37] PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
    S Yokota
    T Nozawa
    T Kanetaka
    K Yamazaki
    T Sato
    N Sakurai
    M Kikuchi
    Pediatric Rheumatology, 11 (Suppl 2)
  • [38] The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
    Shima, Yoshihito
    Kuwahara, Yusuke
    Murota, Hiroyuki
    Kitaba, Shun
    Kawai, Mari
    Hirano, Toru
    Arimitsu, Junsuke
    Narazaki, Masashi
    Hagihara, Keisuke
    Ogata, Atsushi
    Katayama, Ichiro
    Kawase, Ichiro
    Kishimoto, Tadamitsu
    Tanaka, Toshio
    RHEUMATOLOGY, 2010, 49 (12) : 2408 - 2412
  • [39] Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Nanki, Toshihiro
    Umehara, Hisanori
    Yasuda, Nobuyuki
    Tago, Fumitoshi
    Kitahara, Yasumi
    Kawakubo, Makoto
    Torii, Kentaro
    Hojo, Seiichiro
    Kawano, Tetsu
    Imai, Toshio
    MODERN RHEUMATOLOGY, 2023, 34 (01) : 37 - 44
  • [40] EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY
    Mazurov, V.
    Zotkin, E.
    Ilivanova, E.
    Kropotina, T.
    Plaksina, T.
    Nesmeyanova, O.
    Soroka, N.
    Kundzer, A.
    Lutskii, A.
    Dokukina, E.
    Eremeeva, A.
    Zinkina-Orihan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 633 - 634
12345